कंपनी का अवलोकन
KALA BIO, Inc. operates as a clinical-stage biopharmaceutical enterprise dedicated to the research, development, and commercialization of therapeutic interventions specifically targeted at rare and severe ocular conditions. This organization functions within the broader Healthcare sector, with a specialized focus on the Biotechnology industry, positioning itself to address unmet medical needs in ophthalmology. The company currently maintains a market capitalization of $166.77M and employs a workforce of 38 individuals to drive its scientific and operational initiatives. The reported annual revenue figure is not available in the current data set, which suggests that the firm is likely operating at a scale where revenue generation has not yet materialized or is being classified differently for this reporting period.
वित्तीय स्वास्थ्य
The financial statements indicate that the company's revenue for the trailing twelve months is not available, while the net income for the same period stands at -$35,841,000, reflecting a significant net loss. The EBITDA for the trailing twelve months is reported at -$41,311,000, which highlights a substantial gap between operational revenue and profitability, indicating that the cost structure involves heavy expenditures relative to current income streams. The free cash flow is recorded at -$22,026,250, signaling that the company is consuming cash reserves to fund its operations and development pipeline rather than generating positive cash flow from core activities. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which indicates that the company is not yet generating profit from sales or operations, a common characteristic for clinical-stage entities focused on R&D. On the balance sheet, the company holds $21.10M in cash against $29.94M in debt, creating a net cash position that is negative, while the debt-to-equity ratio is not available for calculation. The current ratio stands at 0.74, which suggests that the company's current assets are insufficient to cover its current liabilities, indicating potential liquidity constraints in the short term. Return on Equity is not available, whereas the Return on Assets is reported at -65.8%, revealing that the management's utilization of assets has resulted in a negative return for the asset base.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not available due to the lack of positive earnings, while the forward P/E is listed as -0.03, implying that the market is pricing in future earnings expectations that are currently negative or not yet realized. The price-to-book ratio is -0.16, a figure that is unusual for a public company and typically indicates that the market is valuing the firm at a discount relative to its book value, potentially reflecting high risk or asset-light characteristics. The price-to-sales ratio and EV/EBITDA are also reported as not available or negative (-0.25 respectively), suggesting that traditional valuation multiples based on sales or earnings are not applicable in their standard form. The stock has exhibited significant price volatility, trading between a 52-week low of $0.15 and a 52-week high of $20.60. The current price position relative to this range cannot be calculated as a specific percentage without the exact current share price, but the range itself demonstrates an extreme expansion from the low to the high. The beta value is -1.99, which is a highly anomalous negative figure indicating that the stock's price movements have historically moved in the opposite direction of the broader market with high intensity.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both reported as not available, which precludes a direct comparison of earnings growth speed relative to revenue growth at this specific data point. Since the company does not pay a dividend, the dividend yield is not available and the payout ratio is 0.0%, indicating that the firm retains all available capital for operational needs rather than distributing income to shareholders. The absence of a dividend payout confirms that the company's strategy is to reinvest any generated earnings, or rather any available capital, entirely back into its research and development efforts to advance its clinical trial candidates like KPI-012. The overall growth and income profile is characterized by a complete lack of current profitability and dividend distribution, relying instead on external capital or cash reserves to fund its clinical-stage pipeline.